Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + Toripalimab + mFOLFIRINOX for High-risk or Borderline Resectable Pancreatic Cancer
NCT07469956Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2026
- Primary completion
- Jan 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in pancreatic cancer (PC), sponsored by Sun Yat-sen University. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
surufatinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07469956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07469956.